About PLUS
Himly Lab for Respiratory Health & Nanomedicine
PLUS is a public university with ~18,000 students, ~2,800 employees and a strong track record in EU projects. The Himly Lab at PLUS has participated in 15 EU-funded projects in the field of allergen pharmaceutics, type 2 sensitization, nanosafety, and nanotechnology education: CREATE, NanoTOES, NanoValid, NanoEIS, HUMUNIY, PANDORA, EC4SafeNano, NanoCommons, NanoRIGO, EndoNano, AllPret, CompSafeNano, PINK, PLANETS, and NeuroNanoTech.  Further, Himly led the nanoeducational research project Nan-O-Style with involvement of Austrian schools and has been involved in the allergen standardisation program of the European Directorate for Quality of Medicines and Healthcare (EDQM) and the Paul-Ehrlich Institute. He holds 7 patents, incl. one dedicated to safety assessment of nano-aerosols: “Flatbed air-liquid interface exposure module and methods” and has authored >130 peer-reviewed publications (h-index 41; >5300 citations by Google Scholar in Nov 2024).
PLUS’Â role in PLANETS
In PLANETS, PLUS leads WP8 on Education, Social Sciences & Humanities and Task 6.2 on Lessons Learned. PLUS contributes to SSbD assessment in all three case studies (WP3-5), SSbD harmonization and generalization across sectors & value chains in WP2 and WP6 and stakeholder engagement in WP9.
